Examples of using Hypercalcaemia in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
Hyperkalaemia, cachexia, hypercalcaemia, hypocalcaemia, hypernatraemia,
Supplementation with calcium and vitamin D is required in all patients unless hypercalcaemia is present see section 4.2.
The proportion of patients with at least one SRE(excluding hypercalcaemia) was 29.8% in the Zometa-treated group versus 49.6% in the placebo group p=0.003.
In addition, patients without hypercalcaemia will also receive supplementary doses of calcium
In patients with moderate hypercalcaemia(albumin-corrected serum calcium< 3 mmol/ l or<
Studies in animals have shown hypercalcaemia and reproductive toxicity with high doses of vitamin D see section 5.3.
Copalia HCT is contraindicated in patients with hypercalcaemia and should only be used after correction of any pre-existing hypercalcaemia. .
The recommended dose in hypercalcaemia(albumin-corrected serum calcium 12.0 mg/dl or 3.0 mmol/l)
In most patients with severe hypercalcaemia(albumin-corrected serum calcium*≥3 mmol/l or≥12 mg/dl) 4 mg is an adequate single dose.
In general patients with osteolytic bone metastases require lower doses than patients with the humoral type of hypercalcaemia.
In patients with moderate hypercalcaemia(albumin- corrected serum calcium< 3 mmol/l or<
In the treatment of hypercalcaemia caused by tumours, Bondronat is given over 2 hours as an infusion of either 2 or 4 mg, depending on how severe the hypercalcaemia is.
Rasitrio is contraindicated in patients with hypercalcaemia and should only be used after correction of any pre-existing hypercalcaemia. .
In the treatment of hypercalcaemia caused by tumours, Iasibon is given over 2 hours as an infusion of either 2 or 4 mg, depending on how severe the hypercalcaemia is.
Caution must be exercised in patients with pre-existing hypo- or hypercalcaemia see section 4.8.
the cases hypophosphataemia was present, 19.0% had a tendency for hypercalcaemia and 9.0% for hypocalcaemia.
No pharmacokinetic data for zoledronic acid are available in patients with hypercalcaemia or in patients with hepatic insufficiency.
Untreated hypercalcaemia patients generally have some degree of renal function impairment,
have received a second infusion for hypercalcaemia.
dehydration, gout, hyperuricaemia, hypercalcaemia, hyperglycaemia, hyponatraemia.